National Institute On Drug Abuse

NCI Completes Phase II Trial for Anti-Tac(Fv)-PE38 (LMB-2) in Cutaneous T-Cell Lymphomas

The National Cancer Institute (NCI) completed a Phase II clinical trial (NCT00080535) for Anti-Tac(Fv)-PE38 (LMB-2) in CD25-positive Cutaneous T-cell Lymphomas (CTCL). This recombinant immunotoxin targets CD25-expressing cancer cells. Concluding in 2011 with results posted in 2012, this study provided critical insights into the efficacy and safety profile of LMB-2, informing future targeted oncology development and strategic portfolio planning for novel biologics.